Good morning :)
$
₹
Biohaven Ltd.

Biohaven Ltd.

BHVN

NYSE
Asset Logo

Biohaven Ltd.

BHVN

NYSE
$14.262.77% (+0.38)
$
₹
$14.262.77% (+0.38)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $2.1B the stock is ranked 2091

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

156.20
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-4.56
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 17 analysts reports

Buy
12 analysts
Hold
4 analysts
Sell
1 analyst

Price Upside

+65.23%

Earnings Growth

+77.02%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 65.23% growth, versus a trailing 3-year CAGR of -19.74%.

2026
Current$13.88Baseline
Analyst Target - 1 year
Target$22.93+65.23%

All values in $

202220232024202520262027$19.39$28.62$37.85Target+65.23%
2026
Current$13.88Baseline
Analyst Target - 1 year
Target$22.93+65.23%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$0Baseline
Forecast for Dec 2026
High$350
Average$93.33
Low$0

All values in $ Million

202120222023202420252026462.500000LowAverageHigh
2025
Current$0Baseline
Forecast for Dec 2026
High$350
Average$93.33
Low$0

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-5.64Baseline
Forecast for Dec 2026
High$-0.09+98.41%
Average$-1.3+77.02%
Low$-2.88+48.94%

All values in $

202120222023202420252026-13.08-14.25-5.66-8.72-5.64Low+48.94%Average+77.02%High+98.41%
2025
Current$-5.64Baseline
Forecast for Dec 2026
High$-0.09+98.41%
Average$-1.3+77.02%
Low$-2.88+48.94%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-173.4
-145.5
-130.5
-137.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0003.83000000
Net Income-179.50-319.77-160.30-186.84-221.67-198.14-173.44-145.55-130.53-137.31
Net Profit Margin----4870.77%------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Biohaven Ltd. -156.20-
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare BHVN with any stock or ETF
Compare BHVN with any stock or ETF
Comparing from
BHVN
ABBV
AMGN
Loading...

Frequently asked questions

  1. Biohaven Ltd. (BHVN) share price today is $14.26 as of October 27, 2026 at 12:18 AM IST. The stock touched a day high of $14.67 and a day low of $13.72.

  2. Biohaven Ltd. stock trades on NYSE under the ticker symbol BHVN.

  3. Biohaven Ltd.'s market capitalization is $2.09B as of October 27, 2026 at 12:18 AM IST.

  4. Biohaven Ltd.'s price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Biohaven Ltd.'s price-to-book (P/B) ratio is 156.20 as of October 26, 2026.

  6. Yes, You can buy Biohaven Ltd. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Biohaven Ltd. shares in three steps: 1. Search Biohaven Ltd. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Biohaven Ltd. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Biohaven Ltd. (BHVN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.701 shares at the current price of $14.26.

Loading...